Kazia Therapeutics Files 6-K Report

TL;DR

Kazia Therapeutics (KZA) filed a standard 6-K, confirming 20-F filings and Sydney HQ.

AI Summary

Kazia Therapeutics Limited filed a Form 6-K on October 2, 2024. The filing is a report of a foreign private issuer and indicates that the company files annual reports under Form 20-F. Kazia Therapeutics Limited is incorporated in C3 and has its principal executive offices in Sydney, NSW, Australia.

Why It Matters

This filing provides routine updates for foreign private issuers, informing investors about the company's reporting status and basic corporate information.

Risk Assessment

Risk Level: low — This is a routine administrative filing (6-K) that does not contain material new financial or operational information.

Key Players & Entities

• Kazia Therapeutics Limited (company) — Registrant
• 000-29962 (company) — SEC File Number
• Sydney NSW (location) — Principal executive office location
• Form 20-F (document) — Annual report form
• Form 6-K (document) — Filing type

FAQ

Filing Documents

• d848734d6k.htm (6-K) — 10KB
• d848734dex991.htm (EX-99.1) — 16KB
• g848734kazia.jpg (GRAPHIC) — 12KB
• 0001193125-24-231202.txt ( ) — 43KB

From the Filing

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2024 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On October 2, 2024, Kazia Therapeutics Limited (the Company) issued a press release titled, Kazia Therapeutics Announces Presentation of Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American Society for Radiation Oncology 66th Annual Meeting. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of Dr. John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Companys registration EXHIBIT LIST Exhibit Description 99.1 Press Release of Kazia Therapeutics Limited dated October 2, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: 2 October 2024

View Full Filing

View this 6-K filing on SEC EDGAR